DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT ID: NCT00389779

Last Updated: 2014-03-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

849 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-09-30

Study Completion Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo- and active-controlled study of a new experimental drug called darusentan. Darusentan is not currently approved by the United States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic and diastolic hypertension despite treatment with full doses of three or more antihypertensive drugs, including a diuretic. Subjects will be randomized to darusentan (optimized dose), an active comparator, or placebo, administered orally. The treatment period for this trial is 14 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Darusentan

Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily for 14 weeks

Group Type EXPERIMENTAL

Darusentan

Intervention Type DRUG

Darusentan capsules administered orally once daily

Darusentan Placebo

Intervention Type DRUG

Placebo to match darusentan administered orally once daily

Guanfacine

Placebo to match darusentan for 2-week placebo run-in period, followed by guanfacine 1 mg capsules administered orally once daily for 14 weeks

Group Type ACTIVE_COMPARATOR

Guanfacine

Intervention Type DRUG

Guanfacine capsules administered orally once daily

Darusentan Placebo

Intervention Type DRUG

Placebo to match darusentan administered orally once daily

Darusentan Placebo

Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks

Group Type PLACEBO_COMPARATOR

Darusentan Placebo

Intervention Type DRUG

Placebo to match darusentan administered orally once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Darusentan

Darusentan capsules administered orally once daily

Intervention Type DRUG

Guanfacine

Guanfacine capsules administered orally once daily

Intervention Type DRUG

Darusentan Placebo

Placebo to match darusentan administered orally once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LU 135252

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects who are competent to provide written consent;
2. Aged 35 to 80 years;
3. Subjects with diabetes and/or chronic kidney disease must have an average sitting systolic blood pressure greater than or equal to 130 mmHg;
4. All other subjects must have an average sitting systolic blood pressure greater than or equal to 140 mmHg;
5. Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic;
6. Female subjects of non-childbearing potential (i.e., post-menopausal for at least 2 years or surgically sterile).

Exclusion Criteria

1. Average sitting systolic and diastolic blood pressure greater than or equal to 180 mmHg and 110 mmHg, respectively;
2. Subjects treated with a central alpha-2 agonist and/or imidazoline receptor agonist;
3. Left ventricular dysfunction;
4. Serum ALT or AST greater than 2 times the Upper Limit of Normal;
5. Subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 6 months; or sick sinus syndrome or second or third degree atrioventricular block, atrial fibrillation or recurrent atrial tachycardia, recurrent ventricular tachycardia, or symptomatic bradycardia;
6. Implanted pacemakers or cardioverter defibrillator;
7. Symptomatic congestive heart failure requiring treatment;
8. Hemodynamically significant valvular heart disease;
9. Hemodialysis or peritoneal dialysis, or history of renal transplant;
10. Type I diabetes mellitus;
11. Diagnosis or recurrence of malignancy within the past 3 years;
12. Sleep apnea, unless a recent sleep study demonstrated arterial oxygenation saturation greater than or equal to 90%, treated or untreated;
13. Subjects who perform alternating shift or night work;
14. Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening
Minimum Eligible Age

35 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Gilead Sciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Internal Medicine, PC

Birmingham, Alabama, United States

Site Status

Greystone Medical Research, LLC

Birmingham, Alabama, United States

Site Status

The Heart Center, PC

Huntsville, Alabama, United States

Site Status

Mulberry Medical Associates, PC

Montgomery, Alabama, United States

Site Status

Arizona Center for Clinical Research

Glendale, Arizona, United States

Site Status

Cardiovascular Consultants, Ltd.

Glendale, Arizona, United States

Site Status

Lovelace Scientific Resources, Inc

Phoenix, Arizona, United States

Site Status

Cochise Clinical Research

Sierra Vista, Arizona, United States

Site Status

Southwest Heart

Tucson, Arizona, United States

Site Status

HealthFirst Physician of AR, PA dba Convenient Care Clinic

Hot Springs, Arkansas, United States

Site Status

NEA Clinic

Jonesboro, Arkansas, United States

Site Status

Arkansas Primary Care Clinic, PA

Little Rock, Arkansas, United States

Site Status

Medical Investigations Inc.

Little Rock, Arkansas, United States

Site Status

Highgrove Medical Center

Bakersfield, California, United States

Site Status

Central Cardiology Medical Clinic

Bakersfield, California, United States

Site Status

Impact Clinical Trials

Beverly Hills, California, United States

Site Status

VA Greater Los Angeles Healthcare System

Los Angeles, California, United States

Site Status

Rancho Cucamonga Clinical Trials

Rancho Cucamonga, California, United States

Site Status

Pacific Heart Institute

Santa Monica, California, United States

Site Status

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

Torrance, California, United States

Site Status

Aurora Denver Cardiology Associates

Aurora, Colorado, United States

Site Status

Aurora Denver Cardiology Associates

Aurora, Colorado, United States

Site Status

Clinical Research of South Florida

Coral Gables, Florida, United States

Site Status

Doctors Medical Center of Walton County

DeFuniak Springs, Florida, United States

Site Status

Broward General Medical Center

Fort Lauderdale, Florida, United States

Site Status

Maxine Hamilton, MD, PA

Fort Lauderdale, Florida, United States

Site Status

St. John's Center for Clinical Research

Jacksonville, Florida, United States

Site Status

Private Practice of Dr. Bridget Bellingar

Largo, Florida, United States

Site Status

A+ Research Inc.

Miami, Florida, United States

Site Status

AppleMed Research, Inc.

Miami, Florida, United States

Site Status

Internal Medicine Associates of South Florida

North Miami Beach, Florida, United States

Site Status

Ormond Medical Arts Pharmaceutical Research center

Ormond Beach, Florida, United States

Site Status

Northwest Florida Heart Group, PA - Research Dept

Pensacola, Florida, United States

Site Status

Cardiovascular Center of Sarasota

Sarasota, Florida, United States

Site Status

Suncoast Cardiovascular Research, Inc.

St. Petersburg, Florida, United States

Site Status

Tampa Bay Nephrology Associates, PL

Tampa, Florida, United States

Site Status

Orlando Rangel, MD, PA

Tampa, Florida, United States

Site Status

Medical College of Georgia

Augusta, Georgia, United States

Site Status

AMR Research Associates, LLC

Bogart, Georgia, United States

Site Status

Atlanta Vascular Research Foundation

Tucker, Georgia, United States

Site Status

North Shore Cardiologist

Bannockburn, Illinois, United States

Site Status

Consultants in Cardiovascular Med (CIS)

Melrose Park, Illinois, United States

Site Status

Illinois Heart & Lunch Research

Normal, Illinois, United States

Site Status

Methodist Medical Center-Heart, Lung & Vascular Institute

Peoria, Illinois, United States

Site Status

Medical Consultants, PC

Muncie, Indiana, United States

Site Status

University Medical Associates

Louisville, Kentucky, United States

Site Status

Dr. Jeffrey Chen

Lafayette, Louisiana, United States

Site Status

Louisiana Research Associates, Inc

New Orleans, Louisiana, United States

Site Status

Maine Research Associate

Auburn, Maine, United States

Site Status

PrimeCare Internal Medicine

Biddeford, Maine, United States

Site Status

Great Lakes Heart Center of Alpena

Alpena, Michigan, United States

Site Status

Internal Medicine of Nothern Michigan

Petoskey, Michigan, United States

Site Status

Minneapolis VAMC

Minneapolis, Minnesota, United States

Site Status

Central Minnesota Heart Center at St. Cloud Hospital

Saint Cloud, Minnesota, United States

Site Status

St. Paul Cardiology

Saint Paul, Minnesota, United States

Site Status

Glacier View Cardiology, PC

Kalispell, Montana, United States

Site Status

Impact Clinical Trials

Las Vegas, Nevada, United States

Site Status

NJ Heart

Linden, New Jersey, United States

Site Status

New Jersey Physicians

Passaic, New Jersey, United States

Site Status

Lifeline Research Institute

Brooklyn, New York, United States

Site Status

Metrolina Internal Medicine, PA

Charlotte, North Carolina, United States

Site Status

Heart Care Center of Charlotte

Charlotte, North Carolina, United States

Site Status

Physicians East, PA

Winterville, North Carolina, United States

Site Status

Plaza Medical Group, PC

Oklahoma City, Oklahoma, United States

Site Status

Castlerock Clinical Research Counsultants, LLC

Tulsa, Oklahoma, United States

Site Status

Integrated Medical Research PC

Ashland, Oregon, United States

Site Status

Blackstone Cardiology Associates

Pawtucket, Rhode Island, United States

Site Status

Charleston Cardiology

Charleston, South Carolina, United States

Site Status

Paris View Family Practice

Greenville, South Carolina, United States

Site Status

Internal Medicine of Greer

Greer, South Carolina, United States

Site Status

Scenic City Research

Cleveland, Tennessee, United States

Site Status

Southeast Texas Clinical Research Center

Beaumont, Texas, United States

Site Status

Cardiovascular Research Inst. of Dallas

Dallas, Texas, United States

Site Status

Galenos Research

Dallas, Texas, United States

Site Status

Sergio F Rovner, MD

El Paso, Texas, United States

Site Status

Salim Gopalani, MD, PA

Houston, Texas, United States

Site Status

Humayun Mirza, MD, PA

Houston, Texas, United States

Site Status

Clinical Trial Network

Houston, Texas, United States

Site Status

Houston Clinical Research Assoc.

Houston, Texas, United States

Site Status

Innovative Research of West Florida

Hurst, Texas, United States

Site Status

North Texas Medical Research

Plano, Texas, United States

Site Status

Scott & White Memorial Hospital

Temple, Texas, United States

Site Status

Fletcher Allen Health Care/University of Vermont

Burlington, Vermont, United States

Site Status

Kamlesh N. Dave Cardiology

Hopewell, Virginia, United States

Site Status

WVU Physicians of Charleston

Charleston, West Virginia, United States

Site Status

Alpha Medical Research, LLC

Madison, Wisconsin, United States

Site Status

Executive Health and Research Associates

Madison, Wisconsin, United States

Site Status

Hospital Italiano Regional del Sur

Bahía Blanca, Buenos Aires, Argentina

Site Status

Instituto de Investigaciones Clinicas Bahia Blanca

Bahía Blanca, Buenos Aires, Argentina

Site Status

Instituto de Investigaciones Clinicas Mar del Plata

Mar del Plata, Buenos Aires, Argentina

Site Status

Consultorios Medicos Privados S.A.

Buenos Aires, , Argentina

Site Status

Hospital General de Agudos "Dr. Abel Zubizarreta"

Buenos Aires, , Argentina

Site Status

Policlinica Bancaria "9 de Julio"

Buenos Aires, , Argentina

Site Status

Diabaid (Instituto de Asistencia Integral en Diabetes)

Ciudad de Buenos Aires, , Argentina

Site Status

MD Investigaciones

Ciudad de Buenos Aires, , Argentina

Site Status

Centro Medico Privado

Ciudad de, , Argentina

Site Status

Instituto de Cardiologia de Corrientes

Corrientes, , Argentina

Site Status

Fundacion Rusculleda

Córdoba, , Argentina

Site Status

Framingham Centro Medico

La Plata, , Argentina

Site Status

Instituto de Investigaciones Clinicas de Quilmes

Quilmes, , Argentina

Site Status

Instituto de Investigaciones Clinicas

Rosario, , Argentina

Site Status

Centro de Investigaciones Clinicas del Litoral

Santa Fe, , Argentina

Site Status

Flinders Medical Centre

Bedford Park, , Australia

Site Status

Royal Brisbane & Women's Hospital

Herston, , Australia

Site Status

Alfred Hospital

Melbourne, , Australia

Site Status

Royal Perth Hospital

Perth, , Australia

Site Status

U.Z. Brussel

Brussels, , Belgium

Site Status

Private Practice of Dr. Geert Hollanders

De Pinte, , Belgium

Site Status

Private Practice of Dr. Francis Vrancken

Genk, , Belgium

Site Status

Private Practice of Dr. Herwig Van Aerde

Genk, , Belgium

Site Status

Private Practice of Dr. Willy Denier

Genk, , Belgium

Site Status

Private Practice of Dr. Herman Docx

Hoeilaart, , Belgium

Site Status

Private Practice of Dr. Yohan Balthazar

Natoye, , Belgium

Site Status

Private Practice of Dr. Sophie Baeyens

Pulle, , Belgium

Site Status

Private Practice of Dr. Jean Gilissen

Riemst, , Belgium

Site Status

Private Practice of Dr. Guido Mehuys

Tielt, , Belgium

Site Status

Private Practice of Dr. Luc Capiau

Wetteren, , Belgium

Site Status

Hospital Universitario Pedro Ernesto

Rio de Janeiro, , Brazil

Site Status

Aalborg University Hospital

Aalborg, , Denmark

Site Status

Region Sjaelland, Storstrommens Sygenhus, Naestved

Næstved, , Denmark

Site Status

Private Practice of dr. Marty Jacques

Mûrs-Erigné, Murs-Erigne, France

Site Status

George Delamare

Blois, , France

Site Status

Centre d'Investigation Clinique

Dommartin-lès-Toul, , France

Site Status

Private Practice of Dr. Brune Charrier

La Jubaudière, , France

Site Status

Private Practice of Dr. Jean Boulet-Gercourt

Le Mesnil-en-Vallée, , France

Site Status

Private Practice of Dr. Gildas Ganuchaud

Le Temple-de-Bretagne, , France

Site Status

Private Practice of Dr. Jacques Samat

Martigues, , France

Site Status

Private Practice of Dr. Alain Boye

Nantes, , France

Site Status

Private Practice of Dr. Francois Volny

Nantes, , France

Site Status

Private Practice of Dr. Thierry Schaupp

Vihiers, , France

Site Status

Private Practice of Dr. Josef Junggeburth

Bad Wörishofen, , Germany

Site Status

Charite Campus Mitte, Universitatsmedizin Berlin

Berlin, , Germany

Site Status

Klinische Forschung Berlin-Buch GmbH

Berlin, , Germany

Site Status

Private Practice of Dr. Isabelle Schenkenberger

Berlin, , Germany

Site Status

Private Practice of Dr. Tobias Marsen

Cologne, , Germany

Site Status

PD Dr. med. Bernhard Winkelmann

Frankfurt, , Germany

Site Status

Clinical Research Hamburg

Hamburg, , Germany

Site Status

Dr. Med. Susanne Mindt-Prufert

Hamburg, , Germany

Site Status

Private Practice for Internal Medicine & Cardiology

Heidelberg, , Germany

Site Status

IFG-Institut fur Gesundheitsforderung GmbH

Rüdersdorf, , Germany

Site Status

Centre for Clinical Research and Effective Practice (CCRep)

Auckland, , New Zealand

Site Status

Christchurch Hospital

Christchurch, , New Zealand

Site Status

Greenlane Clinical Centre

Greenlane, , New Zealand

Site Status

Cardiology Clinical Trial Unit

Hamilton, , New Zealand

Site Status

Tauranga Hospital

Tauranga, , New Zealand

Site Status

Hospital Universitario de Bellvitge

Barcelona, , Spain

Site Status

Hospital General Universitario de Elche

Elche, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Belgium Brazil Denmark France Germany New Zealand Spain

References

Explore related publications, articles, or registry entries linked to this study.

Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010 Nov;56(5):824-30. doi: 10.1161/HYPERTENSIONAHA.110.156976. Epub 2010 Oct 4.

Reference Type DERIVED
PMID: 20921430 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Protocol DAR-312

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.